China's Sinovac defends COVID-19 vaccine after disappointing Brazil data
- CoronaVac 50.4% effective in trial including very mild cases.
- Had reported 78% efficacy in mild-to-severe cases.
- Chairman says results are good around the world.
- Malaysia and Singapore seeking more data.